NanoViricides Incorporated — NYSE: NNVC
NYSE
American: NNVC
NNVC PAID ADVERTORIAL *

Clinical-Stage Antiviral Drug Development Company

A Broad-Spectrum, Clinical-Stage
Antiviral Drug Developer on the NYSE
Steadily Hits Milestones

NNVC states: When vaccines fail…when viruses mutate into variants… NanoViricides can conquer!

Noble Initiates "Outperform" Rating with $6 Target View report [xii]
Equiscreen, LLC has been paid fifteen thousand dollars cash from Interactive Offers, LLC for a marketing program regarding NNVC. Owners of Equiscreen, LLC do not own stock in NNVC. See our important Notice and Disclaimer below for a detailed discussion on compensation.

The NanoViricides story has moved quickly in 2026. NV-387 now has FDA Orphan Drug and Rare Pediatric Disease Drug designations for Measles, while ACOREP has approved Phase II clinical trials in the DRC for Ebola and MPox. NV-387 Oral Gummies are already in the DRC Principal Investigators assigned, staff trained and trial sites prepared, and the company said first dosing is expected within weeks in its August 18, 2026 update. The drug is designed to act directly on virus particles through a host-mimetic "Bind-Encapsulate-Destroy" mechanism that is effective even against variants. Noble Capital Markets initiated coverage with an Outperform rating and a $6.00 target; Zacks Small-Cap Research has a $7.00 target. [i] [ii] [iii] [x] [xii] [xiii] [xv]

“We now eagerly await the first dosing of Ebola patients with our NV-387 Oral Gummies drug product that is already in place in DRC. We, our colleagues, and our partners are hoping that this orally available, unique and revolutionary broad-spectrum antiviral drug succeeds in combatting the Bundibugyo virus for which there is no known treatment or vaccine.” [ii]
Four updates define the current story.

Latest NNVC Developments

A rising Measles treatment need, an approved Ebola study moving toward first dosing, NV-387 already in the DRC, and a second FDA designation for the Measles program.

August 31, 2026

Measles program moves toward clinical trials

The company reported 2,903 confirmed U.S. Measles cases as of August 27, versus 2,289 in all of 2025, and said it was preparing NV-387 for Measles clinical trials. Read the update [i]

August 18, 2026

Ebola trial preparations move into the field

Professor Patrick Katoto was appointed principal investigator, while staff training and site preparations continued. The company said first dosing was expected within weeks, subject to conditions on the ground. Read the update [ii]

August 10, 2026

ACOREP approves the Phase II Ebola trial

ACOREP approved a Phase II study of NV-387 Oral Gummies for the current Bundibugyo Ebolavirus and other Ebola viruses. The clinical drug product was already available in the DRC. Read the update [iii]

June 29, 2026

FDA grants Rare Pediatric Disease Drug Designation

The FDA granted Rare Pediatric Disease Drug Designation for NV-387 as a Measles treatment. A Priority Review Voucher would be possible only after approval and satisfaction of all applicable program conditions. Read the update [x]

The steps that led to the current position

Follow the shorter progress trail: Jun 22 - drug shipped | Jul 6 - Ebola program advances | Jul 8 - Noble coverage | Jul 13 - ethics approval | Jul 22 - ACOREP filing | Jul 24 - offering priced | Jul 28 - financing update [xi] [ix] [viii] [vii] [vi] [v] [iv]

Jun 22drug shipped
Jul 6Ebola program advances
Jul 8Noble coverage
Jul 13ethics approval
Jul 22ACOREP filing
Jul 24offering priced
Jul 28financing update
Greeting Investors

The Story Moves from Platform Promise to Clinical Milestones*

A lot changed for NanoViricides in a short period. The company moved NV-387 from regulatory preparation to approved Phase II programs for Ebola and MPox in the DRC, while adding a FDA designation for Measles that could lead to significantly valuable Priority Review Vouchers upon commercialization. [iii] [x]

That shift matters because investors can now follow concrete operating milestones instead of a platform story alone. The drug is in the DRC, the Principal Investigators for the MPOX and Ebola Phase II trials haves been appointed, the Trial sites have been prepared trial teams have been trained and dosing is imminent. [ii]

The questions to watch is concrete: will the successful Phase 1 clinicals safety profile of lead drug NV-387 translate into meaningful Phase II clinical results? The answers should do much to shape the NNVC story and deliver a key inflection point in the company’s valuation.

*Please read the Important Notice and Disclaimer below, including the discussion of compensation, risks, forward-looking statements and the importance of professional investment advice.
Focus on Programs

NNVC's Mission

Focus on Programs Where Treatments Are Limited; Develop Drugs That Work When Vaccines Fail, and Treat Future Viral Outbreaks/Variants On “First Visit” To Prevent Pandemics.

The near-term mission is straightforward: text NV-387 where treatment options are limited and develop one broad-spectrum candidate that could serve more than one outbreak. That has resulted in Phase II clinical trials in the DRC for Ebola and MPox, alongside clinical planning for Measles after the FDA's Orphan Drug and Rare Pediatric Disease Drug designations. [iii] [x] [xi]

NV-387 remains the lead story. Earlier work in RSV, Influenza, COVID-19 and other viruses supports the platform's breadth, while the separate NV-HHV-1 program is aimed at Shingles and other Herpes-family infections. [xvi]

mission
Three Near-Term Clinical Priorities

A development plan coming into sharper focus.

The latest releases bring the development plan into sharper focus:

01

MPox/Smallpox

ACOREP has approved the Phase II MPox study in the DRC, and NV-387 Oral Gummies were shipped there on June 22, 2026. [xi]

02

Measles

FDA Orphan Drug and Rare Pediatric Disease Drug designations support the U.S. development path, while the company prepares for clinical trials. [i] [x]

03

Ebola

ACOREP approved the Phase II study on August 10. A principal investigator is in place, site work is underway, and first dosing was expected within weeks as of August 18, subject to operating conditions. [ii] [iii]

The common starting point is NV-387's Phase I study, which was completed in 2023. The company reported no adverse events and favorable tolerability. [xiv]

NV-387 Phase I clinical trial summary
From FDA designation to field preparation.

Recent Regulatory and Clinical Milestones

A live development record across U.S. regulatory progress and clinical execution in the DRC.

RegulatoryClinical operationsCorporate
Regulatory

FDA granted Orphan Drug Designation for NV-387 as a Measles treatment

Clinical operations

DRC Pillar Committee approved the proposed Phase II Ebola study

Clinical operations

NV-387 Oral Gummies shipped to the DRC for the approved Phase II MPox study

Regulatory

FDA granted Rare Pediatric Disease Drug Designation for NV-387 in Measles

Corporate

Noble Capital Markets initiated Outperform coverage with a $6.00 target

Clinical operations

DRC National Ethics Committee approved the Phase II Ebola study

Regulatory

Phase II Ebola application filed with ACOREP

Corporate

Approximately $3.8 million offering completed; company linked the financing to anticipated Ebola study expenses

Regulatory

ACOREP granted regulatory approval for the Phase II Ebola study

Clinical operations

Principal investigators appointed for MPOX and Ebola trials; training and site preparation underway

Clinical operations

Company reported continued Measles growth and preparation for imminent clinical trials

Company Overview

One Platform, Several Viral Targets

NanoViricides, Inc. (NYSE American: NNVC) is a clinical-stage biotechnology company developing host-mimetic antiviral medicines. Its nanoviricide platform is designed to bind to virus particles, wrap around them and destabilize them before they infect healthy cells. [xv]

01Bind

Host-mimetic targeting is designed to engage viral binding surfaces.

02Encapsulate

The platform is designed to wrap around the virus particle.

03Destroy

Destabilization is intended to stop the virus before healthy-cell infection.

company overview

How the "Bind-Encapsulate-Destroy" Mechanism Works

NV-387 is the lead candidate, with approved Phase II programs for Ebola and MPox and FDA designations supporting its Measles development program. A separate candidate, NV-HHV-1, is being developed for Shingles, Cold Sores and Genital Ulcers within the HerpeCide program. [iii] [x] [xvi]

The company also owns a cGMP-capable, multi-product facility in Shelton, Connecticut. That gives it direct control over clinical supply, manufacturing quality and important process know-how as its programs advance. [xvii]

drug developer
Technology

Visual Overview of the Nanoviricide Platform

The figures below show the company's host-mimetic approach, lead programs, manufacturing capability and Phase I experience. Together, they explain the platform more quickly than another page of promotional copy. [xv]

Technology

A Nanoviricide Attacking a Virus Particle
Resources: Technology | Presentation | Analyst research | Company fact sheet | Latest NNVC news

Nanoviricide Platform
Nanoviricide Platform
Antiviral Opportunity
Known markets addressed by NV-387 in 2025$11B+Potential market described above $20B for empiric ARI/SARI treatment [xviii]
A Multi-Billion-Dollar Antiviral Opportunity

Scale matters. Clinical evidence matters more.

The company estimates that the known markets addressed by NV-387 - including RSV, Influenza, COVID/long COVID, MPox/Smallpox, Measles and Ebola - exceeded $11 billion in 2025. It also describes a potential market above $20 billion if NV-387 is eventually approved for empiric treatment of acute viral respiratory infections. [xviii]

Those estimates help show the scale of the opportunity, but the nearer-term investment case is simpler: can one oral candidate move from Phase I safety into useful clinical evidence across more than one serious viral disease?

HIV Example
Six concrete elements of the current NNVC story.

Top Reasons to Have NNVC on Your Radar*

01

Two approved Phase II programs

ACOREP has approved NV-387 Oral Gummies studies for Ebola and MPox in the DRC. [iii]

02

A human safety foundation

The Phase I program was completed with no reported adverse events and favorable tolerability. [xiv]

03

Drug already in the DRC

Clinical product was shipped for the MPox study and is available as the Ebola team prepares for first dosing. [ii] [xi]

04

FDA support for the Measles path

NV-387 has both Orphan Drug and Rare Pediatric Disease Drug designations for this indication. [x]

05

One platform, several viral targets

The host-mimetic design is intended to attack shared viral entry mechanisms rather than a single strain alone. [xv]

06

Resources for the next stage

NanoViricides owns a cGMP-capable facility in Connecticut, completed an approximately $3.8 million financing, and has new analyst coverage from Noble Capital Markets. [v] [xii]

*Please read the Important Notice and Disclaimer below, including the discussion of compensation, risks, forward-looking statements and the importance of professional investment advice.
Leadership

Multi-talented Leadership Team

Anil R. Diwan, PhD

President & Exec. Chairman

25+ years Pharmaceutical Entrepreneurship
Founder of Nanoviricides & TheraCour
Co-inventor of NanoViricides Technology
Key Patents, Several NIH SBIR Awards

Led Uplisting to NYSE-Amer. in 2013
Raised Over $120M.

PhD (Rice University), BTech (IITB)

Krishna Menon, VMD,MRCS,PhD

Consulting Medical Officer

30+ Years of Pharmaceutical Industry Drug Discovery, Pre-clinical trials, Regulatory
Eli Lilly President’s Award

Key contributor: AZT, GemCitabine, Pemetrexed (Alimta) Development;
Eli-Lilly, Dana-Farber, Beth-Israel, Bayer

Meeta R. Vyas, MBA

CFO

30+ years Experience in Corporations: Performance Improvement, Finance, Growth

Principal, The Gores Group;
CEO, Signature Brands, Inc. : Mr. Coffee GM,$1B GE Appliances Division;
Consultant, McKinsey & Company

MBA (Finance, Columbia U), BS (MIT)

Jayant Tatake, PhD

VP, R&D

30+ Years of Pharmaceutical Industry Experience in Drug Discovery, cGMP Manufacturing, cGLP QA/QC, CRO, Synthesis, Scale-up, Formulations.

QA Asst. Director, InterPharm, Inc.
Co-Inventor of Nanoviricides Technology

PhD (UICT, Mumbai, India)

Mak Jawadekar, PhD

Board Director

35+ Years of Pharmaceutical Industry Experience. Pharma Strategic Consultant. Previously at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Asia Colleague Resource Group, in Pfizer Global R&D.
Business and Research experience in joint ventures, alliance management, contracting, pharma R&D, drug delivery, clinical supply manufacture, etc. Global experience working with United States, Europe, India, Japan, China.

Independent Board Member since February 2020

Hon. Theodore “Todd” Rokita, JD

Board Director

Presently Attorney General, State of Indiana. Former US Rep. from Indiana (4 terms since 2010). Served on several House Committees. Co-owner, Apex Benefits Group, Inc. Extensive executive, team-building, business strategy, and fiscal management expertise in the private sector, alongside his public service leadership experience. Serves or has served as a Member of the Board of Directors of several commercial and charitable institutions.

Independent Board Member since May 2020

Brian M. Zucker, CPA

Board Director

30+ years of experience as a CPA specializing in the securities industry. A Partner at CFO Financial Partners, LLC (https://www.cfopartners.com/). Also serves as the CFO and Financial Operations Principal for numerous broker dealers and hedge funds. Partner at RRBB Accountants & Advisors. CFO of EIG Energy Partners Capital Markets, LLC. Ex-Senior Consultant at Deloitte Haskins & Sells and at Price Waterhouse. Mr. Zucker holds several FINRA licenses.

Independent Board Member since November 2020

In Summary

NanoViricides enters late summer 2026 with a clearer story than it had at the start of the year. NV-387 has a Phase I safety foundation, two approved Phase II programs in the DRC, and both FDA Orphan Drug and Rare Pediatric Disease Drug designations for Measles. [iii] [x] [xiv]

The next chapter is about execution. The most useful signals will be patient dosing, enrollment progress and clinical data - not simply the number of viruses the platform may eventually address.

What to watch next:
Watch 1

First patient dosing in the approved Ebola Phase II study

Watch 2

Enrollment and dosing progress in the approved MPox Phase II study

Watch 3

The design and timing of the planned Measles clinical program

Watch 4

Any new human efficacy or safety data for NV-387

*Please read the Important Notice and Disclaimer below, including the discussion of compensation, risks, forward-looking statements and the importance of professional investment advice.
NYSE American: NNVC

Keep an Eye on NNVC as Its Approved Programs Move Toward Dosing

A broad-spectrum platform entering a new phase of clinical execution.

Live Market Data

NanoViricides, Inc. on NYSE: NNVC

Sources
[i] NanoViricides - While Measles Cases Continue to Increase in the USA and Globally (August 31, 2026). View source
[ii] NanoViricides - Phase II Clinical Trial of NV-387 Oral Gummies for Ebola Expected to Begin Soon (August 18, 2026). View source
[iii] NanoViricides - Regulatory Approval Received for the Phase II Ebola Trial (August 10, 2026). View source
[iv] NanoViricides - Ebola Trial Financing Completed While Regulatory Approval Was Pending (July 28, 2026). View source
[v] NanoViricides - Pricing of Approximately $3.8 Million Registered Direct Offering (July 24, 2026). View source
[vi] NanoViricides - Phase II Ebola Trial Application Filed with ACOREP (July 22, 2026). View source
[vii] NanoViricides - National Ethics Committee Approval for the Phase II Ebola Trial (July 13, 2026). View source
[viii] NanoViricides - Research Analyst Report Rates the Company Outperform (July 8, 2026). View source
[ix] NanoViricides - Ebola Clinical Program Advances in the DRC (July 6, 2026). View source
[x] NanoViricides - FDA Grants Rare Pediatric Disease Drug Designation for NV-387 in Measles (June 29, 2026). View source
[xi] NanoViricides - NV-387 Oral Gummies Shipped to the DRC (June 22, 2026). View source
[xii] Noble Capital Markets / Channelchek - NanoViricides Coverage Initiation Report. View source
[xiii] Zacks Small-Cap Research - NanoViricides Research Report. View source
[xiv] NanoViricides Corporate Presentation - NV-387 Phase I Clinical Trial and Safety Information. View source
[xv] NanoViricides - Technology and Host-Mimetic Nanoviricide Platform. View source
[xvi] NanoViricides - Antiviral Drug Pipeline. View source
[xvii] NanoViricides - Company Overview and Shelton, Connecticut Manufacturing Facility. View source
[xviii] NanoViricides - Broad-Spectrum Antiviral and Empiric ARI/SARI Market Opportunity. View source

GENERAL NOTICE AND DISCLAIMER

Equiscreen, LLC research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on publicly available data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Furthermore, some of the content on this website may contain forward-looking statements found in information made publicly available by the companies we highlight. This forward looking information fits within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding future possible events, expected continual growth of a company, the potential value of its securities, and look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. We therefore strongly encourage that you visit and review any and all financial information made publicly available by highlighted companies.

Any opinions expressed in Equiscreen, LLC reports, company profiles, or other investor relations materials and presentations are subject to change, are expressed and given as of the date of publication, and we disclaim any obligation to advise you of any change in any information contained herein. Equiscreen, LLC and its affiliates may buy and sell shares of securities or options and warrants of the companies mentioned on this website at any time.

The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, Equiscreen, LLC, our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).

Stock market investing is inherently risky. Equiscreen, LLC and its affiliates are not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca. and/or the British Columbia Securities Commission (“BCSC”) at https://www.bcsc.bc.ca/.

Equiscreen, LLC has been compensated by Interactive Offers, LLC to engage in investor awareness services for NanoViricides, Inc. (NYSE American: NNVC). NNVC is a client of Interactive Offers, LLC. A beneficial owner of Equiscreen, LLC is a minority stakeholder of Interactive Offers, LLC, owning less than 10%. Equiscreen, LLC and its affiliates are not affiliates or control persons of Interactive Offers, LLC. Equiscreen, LLC has been compensated $15,000 by Interactive Offers, LLC to engage in investor awareness services for NanoViricides, Inc. (NYSE American: NNVC). Equiscreen and its affiliated entities and partners have been compensated a total of $38,000 related to the engagement of investor awareness services for NNVC. Equiscreen, LLC and its partners and affiliates may buy and sell shares of securities or options and warrants of the companies mentioned on this website at any time.

Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. of Equiscreen, LLC investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services based on the publicly available information of our clients and prepared by our partners.